Characterization of intermediate steps in amyloid beta (Aβ) production under near-native conditions

Journal of Biological Chemistry

Volumn 289, Issue 3, 2014, Pages 1540-1550

  Olsson, Fredrik ^a   Schmidt, Staffan ^a   Althoff, Veit ^b   Munter, Lisa M ^c   Jin, Shaobo ^d   Rosqvist, Susanne ^a   Lendahl, Urban ^d   Multhaup, Gerd ^b,c   Lundkvist, Johan ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c MCGILL UNIVERSITY   (Canada)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; AMYLOID BETAS; AMYLOID PRECURSOR PROTEINS; MOLECULAR MECHANISM; SECRETASES; TRANSMEMBRANE SEQUENCES;

CELL MEMBRANES; CYTOLOGY; GLYCOPROTEINS;

PEPTIDES;

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN 37; AMYLOID BETA PROTEIN 38; AMYLOID BETA PROTEIN 48; AMYLOID BETA PROTEIN 49; AMYLOID BETA PROTEIN 51; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[30-31]; AMYLOID BETA PROTEIN[31-30]; AMYLOID BETA PROTEIN[40-38]; AMYLOID BETA PROTEIN[42-39]; AMYLOID PRECURSOR PROTEIN; GAMMA SECRETASE; UNCLASSIFIED DRUG; APP PROTEIN, HUMAN;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CELL MEMBRANE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; EMBRYO; IMMUNOASSAY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN METABOLISM; PROTEIN PROCESSING; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS REGULATION; SIGNAL TRANSDUCTION; ALZHEIMER DISEASE; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETIC DISORDER; GENETICS; HEK293 CELL LINE; HUMAN; METABOLISM; MUTATION; PATHOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; GENE EXPRESSION REGULATION; GENETIC DISEASES, INBORN; HEK293 CELLS; HUMANS; MUTATION;

EID: 84892631959     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.498246     Document Type: Article

References (23)

1. Bateman, R. J., Xiong, C., Benzinger, T. L., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., Holtzman, D. M., Santacruz, A., Buckles, V., Oliver, A., Moulder, K., Aisen, P. S., Ghetti, B., Klunk, W. E., McDade, E., Martins, R. N., Masters, C. L., Mayeux, R., Ringman, J. M., Rossor, M. N., Schofield, P. R., Sperling, R. A., Salloway, S., Morris, J. C.; Dominantly Inherited Alzheimer Network. (2012) Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 367, 795-804
2. Jack, C. R. Jr, Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., Lesnick, T. G., Pankratz, V. S., Donohue, M. C., and Trojanowski, J. Q. (2013) Tracking pathophysiological processes in Alzheimer's disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12, 207-216
3. Wilquet, V., and De Strooper, B. (2004) Amyloid-beta precursor protein processing in neurodegeneration. Curr. Opin. Neurobiol. 14, 582-588 (Pubitemid 39349619)
4. Goate, A., and Hardy, J. (2012) Twenty years of Alzheimer's disease-causing mutations. J. Neurochem. 120, 3-8
5. Kim, J., Onstead, L,. Randle, S., Price, R., Smithson, L., Zwizinski, C., Dickson, D. W., Golde, T., and McGowan, E. (2007) Aβ40 inhibits amyloid deposition in vivo. J. Neurosci. 27, 627-633 (Pubitemid 46143766)
6. Kumar-Singh, S., Theuns, J., Van Broeck, B., Pirici, D., Vennekens, K., Corsmit, E., Cruts, M., Dermaut, B., Wang, R., and Van Broeckhoven, C. (2006) Mean age-of-onset of familial Alzheimer disease caused by presenilin mutations correlates with both increased Aβ42 and decreased Aβ40. Hum. Mutat. 27, 686-695
7. Duering, M., Grimm, M. O., Grimm, H. S., Schröder, J., and Hartmann, T. (2005) Mean age of onset in familial Alzheimer's disease is determined by amyloid beta 42. Neurobiol. Aging 26, 785-788 (Pubitemid 40249479)
8. Andersson, E. R., Sandberg, R., and Lendahl, U. (2011) Notch signaling: Simplicity in design, versatility in function. Development 138, 3593-3612
9. Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., Kang, D. E., Marquez-Sterling, N., Golde, T. E., and Koo, E. H. (2001) A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 414, 212-216 (Pubitemid 33051236)
10. Borgegard, T., Juréus, A., Olsson, F., Rosqvist, S., Sabirsh, A., Rotticci, D., Paulsen, K., Klintenberg, R., Yan, H., Waldman, M., Stromberg, K., Nord, J., Johansson, J., Regner, A., Parpal, S., Malinowsky, D., Radesater, A. C., Li, T., Singh, R., Eriksson, H., and Lundkvist, J. (2012) First and second generation γ-secretase modulators (GSMs) modulate amyloid-beta (Aβ) peptide production through different mechanisms. J. Biol. Chem. 287, 11810-11819
11. Kukar, T. L., Ladd, T. B., Bann, M. A., Fraering, P. C., Narlawar, R., Maharvi, G. M., Healy, B., Chapman, R., Welzel, A. T., Price, R. W., Moore, B., Rangachari, V., Cusack, B., Eriksen, J., Jansen-West, K., Verbeeck, C., Yager, D., Eckman, C., Ye, W., Sagi, S., Cottrell, B. A., Torpey, J., Rosenberry, T. L., Fauq, A., Wolfe, M. S., Schmidt, B., Walsh, D. M., Koo, E. H., and Golde, T. E. (2008) Substrate-targeting γ-secretase modulators. Nature 453, 925-929
12. Richter, L., Munter, L. M., Ness, J., Hildebrand, P. W., Dasari, M., Unterreitmeier, S., Bulic, B., Beyermann, M., Gust, R., Reif, B., Weggen, S., Langosch, D., and Multhaup, G. (2010) Amyloid beta 42 peptide (Aβ42)- lowering compounds directly bind to Abeta and interfere with amyloid precursor protein (APP) transmembrane dimerization. Proc. Natl. Acad. Sci. U.S.A. 107, 14597-14602
13. Ebke, A., Luebbers, T., Fukumori, A., Shirotani, K., Haass, C., Baumann, K., and Steiner, H. (2011) Novel γ-secretase enzyme modulators directly target presenilin protein. J. Biol. Chem. 286, 37181-37186
14. Ohki, Y., Higo, T., Uemura, K., Shimada, N., Osawa, S., Berezovska, O., Yokoshima, S., Fukuyama, T., Tomita, T., and Iwatsubo, T. (2011) Phenylpiperidine-type γ-secretase modulators target the transmembrane domain 1 of presenilin 1. EMBO J. 30, 4815-4824
15. Takami, M., Nagashima, Y., Sano, Y., Ishihara, S., Morishima-Kawashima, M., Funamoto, S., and Ihara, Y. (2009) γ-Secretase: Successive tripeptide and tetrapeptide release from the transmembrane domain of β-carboxyl terminal fragment. J. Neurosci. 29, 13042-13052
16. Okochi, M., Tagami, S., Yanagida, K., Takami, M., Kodama, T. S., Mori, K., Nakayama, T., Ihara, Y., and Takeda, M. (2013) γ-Secretase modulators and presenilin 1 mutants act differently on presenilin/β-secretase function to cleave Aβ42 and Aβ43. Cell Rep 3, 42-51
17. Chávez-Gutiérrez, L., Bammens, L., Benilova, I., Vandersteen, A., Benurwar, M., Borgers, M., Lismont, S., Zhou, L., Van Cleynenbreugel, S., Esselmann, H., Wiltfang, J., Serneels, L., Karran, E., Gijsen, H., Schymkowitz, J., Rousseau, F., Broersen, K., and De Strooper, B. (2012) The mechanism of γ-secretase dysfunction in familial Alzheimer disease. EMBO J. 31, 2261-2274
18. Eriksen, J. L., Sagi, S. A., Smith, T. E., Weggen, S., Das, P., McLendon, D. C., Ozols, V. V., Jessing, K. W., Zavitz, K. H., Koo, E. H., and Golde, T. E. (2003) NSAIDs and enantiomers of flurbiprofen target β-secretase and lower Aβ42 in vivo. J. Clin. Invest. 112, 440-449 (Pubitemid 38063773)
19. Portelius, E., Dean, R. A., Gustavsson, M. K., Andreasson, U., Zetterberg, H., Siemers, E., and Blennow, K. (2010) AnovelAβ isoform pattern in CSF reflects γ-secretase inhibition in Alzheimer disease. Alzheimers Res. Ther. 2, 7
20. Munter, L. M., Botev, A., Richter, L., Hildebrand, P. W., Althoff, V., Weise, C., Kaden, D., and Multhaup, G. (2010) Aberrant amyloid precursor protein (APP) processing in hereditary forms of Alzheimer disease caused by APP familial Alzheimer disease mutations can be rescued by mutations in the APP GxxxG motif. J. Biol. Chem. 285, 21636-21643
21. Portelius, E., Price, E., Brinkmalm, G., Stiteler, M., Olsson, M., Persson, R., Westman-Brinkmalm, A., Zetterberg, H., Simon, A. J., and Blennow, K. (2011) A novel pathway for amyloid precursor protein processing. Neurobiol. Aging 32, 1090-1098
22. Kounnas, M. Z., Danks, A. M., Cheng, S., Tyree, C., Ackerman, E., Zhang, X., Ahn, K., Nguyen, P., Comer, D., Mao, L., Yu, C., Pleynet, D., Digregorio, P. J., Velicelebi, G., Stauderman, K. A., Comer, W. T., Mobley, W. C., Li, Y. M., Sisodia, S. S., Tanzi, R. E., and Wagner, S. L. (2010) Modulation of γ-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. Neuron 67, 769-780
23. Coric, V., van Dyck, C. H., Salloway, S., Andreasen, N., Brody, M., Richter, R. W., Soininen, H., Thein, S., Shiovitz, T., Pilcher, G., Colby, S., Rollin, L., Dockens, R., Pachai, C., Portelius, E., Andreasson, U., Blennow, K., Soares, H., Albright, C., Feldman, H. H., and Berman, R. M. (2012) Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch. Neurol. 69, 1430-1440